This excerpt taken from the ELN 20-F filed Feb 26, 2009.
In the U.S. market, we recorded net sales of $421.6 million (2007: $217.4 million; 2006: $28.2 million). Almost all of these sales are in relation to the MS indication.
As of the end of December 2008, approximately 20,200 patients were on commercial therapy, which represents an increase of 57% since the end of December 2007.
On January 14, 2008, the FDA approved the sBLA for Tysabri for the treatment of patients with CD, and Tysabri was launched in this indication at the end of the first quarter of 2008. On December 12, 2008, we announced a realignment of our commercial activities in Tysabri for CD, shifting our efforts from a traditional sales model to a model based on clinical support and education.